<DOC>
	<DOCNO>NCT02318043</DOCNO>
	<brief_summary>Adenosine monophosphate ( AMP ) may reflect airway inflammation hyperresponsiveness , relationship AMP histamine ( His , conventional stimulus ) bronchial provocation test ( BPT ) asthma fully elucidate . The investigator aim compare BPTs determine usefulness reflect change asthmatic symptom . BPTs perform cross-over fashion , 2-4day interval . Cumulative dos elicit 20 % FEV1fall ( PD20FEV1 ) , diagnostic performance adverse event compare . Patients PD20FEV1 low geometric mean define responder , otherwise poor responder . Patients uncontrolled partly control asthma , maintain original inhaled corticosteroid therapy , underwent reassessment airway responsiveness asthmatic symptom 3 6 month .</brief_summary>
	<brief_title>AMP-BPT His-BPT Assessment Asthma</brief_title>
	<detailed_description>Airway hyperresponsiveness , pivotal feature asthma , assess bronchial provocation test ( BPTs ) , may elicit bronchoconstriction via inhalation stimulus . Histamine direct stimulus induce bronchoconstriction via vasodilation , eosinophil chemotaxis tissue edema . Clinically , histamine BPT ( His-BPT ) gain extensive application decade owe assay sensitivity feasibility , could ideally predict anti-inflammatory treatment outcome practice . Additionally , mild adverse event ( flush hoarseness ) insufficient capacity identify exercise-induced asthma hamper clinical application . Adenosine monophosphate ( AMP ) inflammatory mediator serf indirect bronchial stimulus detect airway hyperresponsiveness asthma . Compared histamine , AMP may pathophysiologically relevant airway inflammation hyperresponsiveness link presence magnitude atopy . However , difference response AMP-BPT His-BPT different asthma control level association asthmatic symptom score fully elucidate . We hypothesize asthmatic patient , regardless control level , respond differentially AMP-BPT His-BPT , great reduction airway responsiveness AMP ( esp . responder AMP-BPT ) associate significant symptom alleviation . Henceforth , seek : 1 ) compare diagnostic performance safety AMP-BPT His-BPT different asthma control level ; 2 ) determine association airway responsiveness asthmatic symptom score . Currently , His-BPT recommend Chinese guideline share considerable similarity methacholine ( another conventional stimulus ) BPT , therefore perform latter study .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Adenosine</mesh_term>
	<mesh_term>Histamine</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<criteria>1. age 18~65 year ; 2. nil respiratory infection within 3 week ; 3. normal chest radiography ; 4. baseline FEV1 &gt; 60 % predict ; 5. withdrawn , , oral leukotriene modifier , corticosteroid antihistamine 5 day , oral xanthenes longacting bronchodilator 2 day , inhaled corticosteroid ( ICSs ) 24 hour , salbutamol 6 hour 1 . FEV1 fall â‰¥20 % follow saline inhalation ; 2. chronic low respiratory disease ( i.e . COPD ) ; 3. severe systemic disease ( i.e . uncontrolled hypertension , malignancy ) ; 4. limit understanding . For healthy subject , age 18~65 year nil respiratory infection within 3 week , systemic disease normal lung function .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>adenosine monophosphate</keyword>
	<keyword>histamine</keyword>
	<keyword>bronchial provocation test</keyword>
	<keyword>asthma symptom score</keyword>
	<keyword>asthma control</keyword>
</DOC>